CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib

Leuk Res. 2005 Nov;29(11):1365-6. doi: 10.1016/j.leukres.2005.04.001.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Benzamides
  • Cytogenetic Analysis / methods
  • Exons
  • Fusion Proteins, bcr-abl / genetics*
  • Genetic Variation*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction / methods
  • Reverse Transcriptase Polymerase Chain Reaction / methods

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl